ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 1550 • ACR Convergence 2022

    Involvement of Iliofemoral Arteries in PET/CT Are Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis

    SEMA KAYMAZ-TAHRA1, Salih Ozguven2, Nuh Filizoglu2, Ali Ugur Unal3, Fatma Alibaz-Oner4, Tunc Ones2, Tanju Yusuf Erdil2 and Haner Direskeneli5, 1Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Rheumatology, Istanbul, Turkey, 2Marmara University School of Medicine, Department of Nuclear Medicine, Istanbul, Turkey, 3Marmara University School of Medicine, Rheumatology, Istanbul, Turkey, 4Marmara University, Rheumatology, Istanbul, Turkey, 5Marmara University, Rheumatology, Istanbul, Istanbul, Turkey

    Background/Purpose: Iliofemoral artery disease, which is commonly observed in severe atherosclerosis, may also be present in Takayasu's arteritis (TAK). In this study we aimed to…
  • Abstract Number: 1574 • ACR Convergence 2022

    Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System

    Alicia Rodriguez-Pla, Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Vasculitides have been reported as adverse events (AEs) related to a wide variety of medications. We aimed to analyze the vasculitides reported to a…
  • Abstract Number: 2230 • ACR Convergence 2022

    Ultra-Rare Genetic Variation in Relapsing Polychondritis: A Whole-Exome Sequencing Study

    Yiming Luo1, Marcela Ferrada1, Keith Sikora2, Daniel Kastner3, Zuoming Deng4, Mengqi Zhang5, Hugh Alessi1, Virginia Kraus6, Andrew Allen6 and Peter Grayson7, 1National Institutes of Health, Bethesda, MD, 2National Institutes of Health Clinical Center, Bethesda, MD, 3National Human Genome Research Institute, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5University of Pennsylvania, Philadelphia, PA, 6Duke University, Durham, NC, 7National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Relapsing polychondritis (RP) is a rare rheumatic disease of unknown etiology characterized by inflammations of cartilaginous structures and other tissues, particularly the ears, nose,…
  • Abstract Number: 0462 • ACR Convergence 2022

    Increasing Incidence of Large Artery Manifestations in Patients with Giant Cell Arteritis, a Population-based Cohort over 70 Years

    Mohanad Elfishawi1, Mahmut Kaymakci2, Sara Achenbach3, Cynthia Crowson4, Tanaz Kermani5, Cornelia Weyand4, Matthew J. Koster1 and Kenneth J. Warrington1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, 3Mayo Clinic, Rochester, MN, Rochester, MN, 4Mayo Clinic, Eyota, MN, 5University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Screening for large artery manifestations has been adopted by clinicians managing patients with Giant Cell Arteritis (GCA). The contemporary effect of the increased use…
  • Abstract Number: 0487 • ACR Convergence 2022

    A Systematic Literature Review to Generate Descriptors for the Development of New Response Criteria in Giant Cell Arteritis

    Catalina Sanchez Alvarez1, Milena Bond2, Medha Soowamber3, Dario Camellino4, Zahi Touma5, Sofia Ramiro6, Melanie Anderson7, Carol Langford8 and Christian Dejaco9, 1University of Florida, Gainesville, FL, 2Hospital of Brunico (SABES-ASDAA), Brunico, Italy, 3Mount Sinai Hospital, Woodbridge, ON, Canada, 4Azienda Sanitaria Locale 3 Genoa, Genoa, Italy, 5Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 6Leiden University Medical Center, Leiden, Netherlands, 7University Health Network, Toronto, ON, Canada, 8Cleveland Clinic, Cleveland, OH, 9Azienda Sanitaria Alto Adige, Brunico, Italy

    Background/Purpose: Giant cell arteritis (GCA) is the most common form of large vessel vasculitis. While remission and relapse are common primary endpoints in clinical trials,…
  • Abstract Number: 1075 • ACR Convergence 2022

    Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype

    Benjamin Terrier1, David Jayne2, Bernhard Hellmich3, Jane Bentley4, Jonathan Steinfeld5, Steven Yancey6, Namhee Kwon7, Praveen Akuthota8, Paneez Khoury9, Lee Baylis10 and Michael Wechsler11, 1National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 2University of Cambridge, Cambridge, United Kingdom, 3Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, 4Clinical Statistics, GlaxoSmithKline, Brentford, United Kingdom, 5Clinical Sciences, Respiratory, GSK (affiliation at time of research), Philadelphia, PA, 6Respiratory Therapeutic Area, GSK (affiliation at the time of research), Research Triangle Park, NC, 7Clinical Sciences, Respiratory, GSK, Brentford, United Kingdom, 8Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California, San Diego, CA, 9Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 10Global Medical Affairs, GlaxoSmithKline, Durham, NC, 11Department of Medicine, National Jewish Health, Denver, CO

    Background/Purpose: Patients with eosinophilic granulomatosis with polyangiitis (EGPA) can have vasculitic or eosinophilic phenotypes. The MIRRA study demonstrated that patients with EGPA spent more time…
  • Abstract Number: 1551 • ACR Convergence 2022

    The Utility of Imaging Studies (MRA and CTA) in Long-Term Monitoring for Patients with Takayasu Arteritis

    Saja Almaaitah1, Chao Zhang2 and alexandra villa forte1, 1Cleveland Clinic Foundation, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH

    Background/Purpose: Takayasu Arteritis (TA) is a complex large vessel vasculitis that leads to arterial stenosis, occlusion and aneurysmal formation. Assessment of disease activity is a…
  • Abstract Number: 1575 • ACR Convergence 2022

    Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis

    Jason Springer1, Tanaz Kermani2, Dianne Shaw3, Kalen Larson4, Cristina Burroughs5 and Peter Merkel6, 1Vanderbilt University Medical Center, Nashville, TN, 2University of California Los Angeles, Los Angeles, CA, 3Vasculitis Foundation, Chapel Hill, NC, 4Vasculitis Foundation, Kansas City, MO, 5University of South Florida, Tampa, FL, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Urticarial vasculitis is a markedly rare disease, with an annual incidence of < 1 per million. Hypocomplementemia is associated with systemic features and a…
  • Abstract Number: 2232 • ACR Convergence 2022

    Clinical Features and Long-term Outcomes of Patients with Systemic Polyarteritis Nodosa Diagnosed Since 2005: Data from 196 Patients

    Julien ROHMER1, ludovic trefond2, Yann Nguyen3, Christian Agard4, Jean Sebastien ALLAIN5, Alice Berezne6, Pierre Charles7, Pascal Cohen8, guillaume gondran9, Matthieu GROH10, Tessa HUSCENOT11, carole lacout12, Estibaliz Lazaro13, Jonathan London14, Francois Maurier15, Arsene Mekinian16, Isabelle Nubourgh17, Rafik MESBAH18, Xavier Puéchal8, Laurent Perard19, Mathieu Puyade20, Gregory Pugnet21, Viviane Queyrel22, Diane Rouzaud23, Arthur Roux24, Cecile-Audrey DUREL19, Loïc Guillevin8 and Benjamin Terrier8, 1APHP, Suresnes, France, 2Chu clermont ferrand, Clermont-Ferrand, France, 3AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, 4Internal medicine, Nantes University Hospital, Nantes, France, 5CHU rennes, Rennes, 6CH Annecy, Annecy, France, 7Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, 8National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 9CHU limoges, Limoges, France, 10Foch Hospital, Suresnes, France, 11APHP, Boulogne, France, 12CHU Angers, Angers, France, 13Bordeaux Hospital University, Bordeaux, France, 14Hôpital Croix-Saint-Simon, Paris, France, 15Hôpitaux privés de Metz, Metz, France, 16AP-HP, Hopital Saint Antoine, Paris, France, 17Ch St Pierre, Brussels, Belgium, 18Boulogne Ch, Boulogne, France, 19CHU Lyon, Lyon, France, 20Centre Hospitalier Universitaire de Poitiers, Poitiers, France, 21CHU Toulouse Purpan Service de Medecine Interne, Toulouse, France, 22CHU NIce, Nice, France, 23Bichat, Paris, France, 24MGEN, Paris, France

    Background/Purpose: The etiological landscape of systemic polyarteritis nodosa (PAN) has substantially changed since the onset of hepatitis B virus (HBV) vaccination and the discovery of…
  • Abstract Number: 0038 • ACR Convergence 2022

    STING Antagonist (IFM4490) Inhibits STING Activation and STING Dependent Signal Transduction in Patients with STING-associated Vasculopathy with Onset in Infancy (SAVI)

    Sachin Gaurav1, Bin Lin2, Sophia Park3, Shankar Venkatraman4, David Winkler4 and Raphaela Goldbach-Mansky5, 1Translational Autoinflammatory Diseases Section, LCIM, NIAID,, Bethesda, MD, 2NIH, Bethesda, MD, 3NIAID, Bethesda, MD, 4IFM Therapeutics, Boston, MA, 5NIH/NIAID, Potomac, MD

    Background/Purpose: SAVI is a rare, autoinflammatory type I interferonopathy caused by gain-of-function mutations that cause STING activation and excessive production of type I interferons and…
  • Abstract Number: 0463 • ACR Convergence 2022

    Utilization of a Giant Cell Arteritis Fast-Track Program Independent of Ultrasound at a Single Center

    Christina Costeas, Shubhasree Banerjee, Madhura Tamhankar, Naomi Amudala, Peter Merkel and Rennie Rhee, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The Giant Cell Arteritis (GCA) Fast-Track program was implemented at our center with the goal of accelerating diagnosis of this rare and rapidly progressive…
  • Abstract Number: 0488 • ACR Convergence 2022

    Discrepancies in Temporal Artery Biopsy Positivity Rate Among White and Black Patients Suspected of Having Giant Cell Arteritis: Experience from a Tertiary Academic Medical Center

    Raj Vachhani1, Peng Li2, Mehdi Tavakoli2, Lanning Kline2 and Angelo Gaffo2, 1University of Alabama at Birmingham, Homewood, AL, 2University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: A prior study evaluated incidence rates of biopsy proven giant cell arteritis (GCA) among black and white patients, concluding that GCA occurs at a…
  • Abstract Number: 1076 • ACR Convergence 2022

    ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain

    Naomi Patel1, David Jayne2, Peter Merkel3, Pirow Bekker4, yuqing zhang5, Huibin Yue4 and John Stone6, 1Massachusetts General Hospital, Sale Creek, TN, 2University of Cambridge, Cambridge, United Kingdom, 3University of Pennsylvania, Philadelphia, PA, 4ChemoCentryx, San Juan Capistrano, CA, 5Massachusetts General Hospital, Quincy, MA, 6Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: The ADVOCATE trial (Jayne DRW et al, N Engl J Med, 2021) was a randomized, double-blind, controlled trial of avacopan vs prednisone in addition…
  • Abstract Number: 1552 • ACR Convergence 2022

    Rare Variant Analysis of Aortopathy Genes in Takayasu’s Arteritis

    Hugh Alessi1, Yiming Luo1, Kaitlin Quinn2 and Peter Grayson3, 1NIH, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: A set of genes has been associated with aortopathies, which are defined as non-inflammatory diseases where the integrity of large arteries is compromised leading…
  • Abstract Number: 1576 • ACR Convergence 2022

    Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortitis

    Umar Ghaffar1, Hannah Langenfeld2, Cynthia Crowson3, Tanaz Kermani4, Michelle Burke1, Boyd Viers1, Aaron Potretzke1, Haraldur Bjarnason1, Kenneth J. Warrington1 and Matthew J. Koster1, 1Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Eyota, MN, 4University of California Los Angeles, West Hills, CA

    Background/Purpose: To evaluate the presentation features and outcomes of patients with chronic abdominal periaortitis in a large referral cohort. Methods: Using a proprietary medical text…
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 41
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology